PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2019.1832020521149-166Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic CancerMei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Ohhttp://e-crt.org/upload/pdf/crt-2019-183.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2019.183, http://e-crt.org/upload/pdf/crt-2019-183.pdf
10.21203/rs.3.rs-19938/v12020MIIP downregulates PD-L1 expression through HDAC6 in malignant melanomaRuwei Xing, Ting Li, Lijie Xiang, Haotian Liu, Junqiang Wei, Jia Lu, Jilong Yanghttps://www.researchsquare.com/article/rs-19938/v1, https://www.researchsquare.com/article/rs-19938/v1.html
Bulletin du Cancer10.1016/j.bulcan.2017.11.01220181053263-274Expression de PD-L1 et inhibiteurs de la voie PD-1/PD-L1 dans le cancer du seinAudrey Monneur, Anthony Gonçalves, François Bertuccihttps://api.elsevier.com/content/article/PII:S0007455118300079?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0007455118300079?httpAccept=text/plain
10.21203/rs.2.24485/v12020Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancerChao Zhang, Wen An, Yuen Tan, Huimian Xuhttps://www.researchsquare.com/article/rs-15044/v1, https://www.researchsquare.com/article/rs-15044/v1.html
Current Oncology10.3747/co.25.39762018254324-334Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung CancerD.E. Meyers, P.M. Bryan, S. Banerji, D.G. Morrishttp://current-oncology.com/index.php/oncology/article/viewFile/3976/2857, http://current-oncology.com/index.php/oncology/article/viewFile/3976/2766, https://www.mdpi.com/1718-7729/25/4/3976/pdf
Gastroenterology10.1016/s0016-5085(17)30942-320171525S189Effectiveness of PD-L1 Inhibition as a Therapeutic Option of Cancer Immunotherapy in Pancreatic CancerEri Kameta, Wataru Shibata, Takeshi Sato, Soichiro Sue, Shin Maedahttps://api.elsevier.com/content/article/PII:S0016508517309423?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508517309423?httpAccept=text/plain
Therapeutic Advances in Urology10.1177/1756287215597647201576365-377Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaMatthew Weinstock, David McDermotthttp://journals.sagepub.com/doi/pdf/10.1177/1756287215597647, http://journals.sagepub.com/doi/full-xml/10.1177/1756287215597647, http://journals.sagepub.com/doi/pdf/10.1177/1756287215597647
BMJ10.1136/bmj.k35292018k3529Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysisXian Shen, Bin Zhaohttp://data.bmj.org/tdm/10.1136/bmj.k3529, https://syndication.highwire.org/content/doi/10.1136/bmj.k3529
Journal for ImmunoTherapy of Cancer10.1136/jitc-2019-000157corr1202081e000157corr1Correction:HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinomahttps://syndication.highwire.org/content/doi/10.1136/jitc-2019-000157corr1
Disease Markers10.1155/2020/8843146202020201-7PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic CancerLei Zhao, Yaming Caohttp://downloads.hindawi.com/journals/dm/2020/8843146.pdf, http://downloads.hindawi.com/journals/dm/2020/8843146.xml, http://downloads.hindawi.com/journals/dm/2020/8843146.pdf